Atlas Trials

A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Clinical trial NCT04616040 · NOT_YET_RECRUITING

Trial details

NCT number
NCT04616040
Sponsor
Peking University
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Esophageal Cancer
Start date
2020-12-01
Primary completion
2023-12-01
Enrollment
1030

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.